Dysregulated microRNAs (miRNAs) have an important role in many malignant tumors. However, elucidating the roles of miRNAs in cancer biology, especially in epithelial cancers, remains an ongoing process. In this study, we show that both miR-143 and miR-145, which belong to the same miRNA cluster, can negatively modulate expression of their target gene, MDM2. The miR-143 and miR-145 is posttranscriptionally activated by upregulated p53, thereby generating a short miRNAs-MDM2-p53 feedback loop. Re-expression of these miRNAs suppresses cellular growth and triggers the apoptosis of epithelial cancer, in vitro and in vivo, by enhancing p53 activity via MDM2 turnover. Moreover, the miRNA-dependent MDM2 turnover contributes to the equilibrium of repeated p53 pulses in response to DNA damage stress. These findings suggest that MDM2 dysregulation caused by downregulation of miR-143 and miR-145 contributes to epithelial cancer development and has a key role in regulating cellular proliferation and apoptosis. Re-expression of miR-143 and miR-145 may be a reasonable strategy for treatment of epithelial cancers.
INTRODUCTION
Carcinomas that originate from epithelial cells, including those of the head and neck, breast, lung, prostate, uterus and colon are by far the most common types of cancer. For example, head and neck squamous cell carcinomas (HNSCCs), one kind of epithelial malignancies originated from squamous epithelia, rank among the 10 most common cancers worldwide, and there are more than 500,000 new cases diagnosed each year. 1 It is widely accepted that an accumulation of genetic and epigenetic alterations in oncogenes and tumor suppressor genes leads to the progression of a normal cell to a malignant cell. 2 Recently, evidence has arisen that a key pathway, the murine double minute 2 (MDM2)-p53 feedback loop, is impaired in HNSCCs. 3 Inactivation of the p53 protein may be caused by a p53 gene mutation or by the p53 protein binding to other proteins, such as MDM2. 4 MDM2 is an E3 ubiquitin ligase that binds to p53 to promote ubiquitination and degradation of the protein. 5 Overexpression of MDM2 is found often in certain types of cancers, indicating that MDM2 has an important role in tumorigenesis. 6 It has been reported that inhibition of MDM2 expression in cancer cells can reactivate p53, leading to apoptosis. 7 Although it has been suggested that MDM2 undergoes ubiquitination when cells are challenged with DNA-damaging agents, 8 results from a recent study have indicated that MDM2 expression remains downregulated, even after excluding the impact of ubiquitination on some cell cycle processes. 9 This finding strongly suggests that the destruction of MDM2 is controlled by an unknown pathway.
Recent studies have suggested that there is an association between MDM2 expression and the biogenesis of microRNA (miRNAs). 10 miRNAs are important post-transcriptional regulators of gene expression that control diverse physiological and pathological processes. 11 The importance of miRNA in cancer is highlighted by the observation that about 50% of miRNAs are located in cancer-associated genomic regions or fragile sites that are frequently amplified or deleted in tumorigenesis. 12 Recently, Pichiorri et al. 10 have identified miRNAs that directly target MDM2 in multiple myeloma originated from hematological tissues and induce cell cycle arrest in a p53-dependent manner.
In this study, we demonstrate that miR-143 and miR-145 directly regulate MDM2 expression and are posttranscriptionally activated by p53 in HNSCCs originated from epithelial tissues. High levels of miR-143 and miR-145 can result in the apoptosis of p53 wild-type HNSCCs cells and can inhibit both in vitro and in vivo cellular proliferation by reducing MDM2 and enhancing p53 activity. Therefore, miR-143/145, MDM2 and p53 form a regulatory network that helps to control the cellular proliferation and apoptosis of HNSCCs cells.
RESULTS

MDM2
and miR-143/145 expression are inversely correlated in HNSCCs Using real-time PCR and western blotting analysis, we analyzed MDM2 mRNA expression in 65 HNSCCs tissue samples, 24 normal oral epithelial tissues and 9 HNSCCs cell lines ( Figure 1a ;
Supplementary Figures S1a and b) . We found that MDM2 mRNA expression is significantly upregulated in HNSCCs tissue samples and cell lines (P ¼ 0.000). In addition, we evaluated the expression of miR-143 and miR-145 in the same panel of HNSCCs samples and cell lines using real-time PCR. The HNSCCs tissues and cell lines had significantly decreased levels of mature miR-143 and miR-145 compared with normal tissues (P ¼ 0.000; Figures 1b and c) and normal cells (Supplementary Figures S1c and d) .
Using non-parametric tests, we found a significant inverse correlation between MDM2 mRNA and miR-143/145 expression in the HNSCCs samples (R 2 ¼ 0.6195 for MDM2 and miR-143; R 2 ¼ 0.6141 for MDM2 and miR-145; Figures 1d and e) . In addition, the MDM2-positive and miR-143/145-negative expression patterns were significantly associated with poorly differentiated tumor grades (Supplementary Table S1 ).
MDM2 is the direct target of miR-143 and miR-145 Increased expression of miR-143 and miR-145 upon transfection was confirmed by real-time PCR (Supplementary Figures S2a and  b) , and the effects on MDM2 and p53 levels were analyzed by western blot (Figure 2a) . The ectopic expression of miR-143 and miR-145 significantly reduced the level of MDM2 48 h after transfection as shown by density-metric analysis (Figure 2d) . Expression of the p53 protein was increased in the HN30 cells transfected with miR-143 and miR-145 mimics (Figures 2a and d) . Furthermore, we confirmed that MDM2 mRNA levels were strongly reduced in the miR-143 and miR-145-transfected cells (Figure 2c (Figure 3a ; Supplementary Figure S3) . We cloned the partial 3 0 UTRs of MDM2 into the pGL3 reporter vector downstream of the luciferase open-reading frame. We found that 293 T cells transfected with the luciferase reporter plus miR-143 and miR-145 exhibited significantly less luciferase activity than did cells that received the reporter plus the miR-NC (Figure 3b ). Using this luciferase reporter system, we found that the inhibition of luciferase activity by miR-143 and miR-145 was dose dependent (Figure 3c ). To test the specificity of miR-143 and miR-145, we showed that miRNA inhibitors specifically abolished the luciferase activity inhibition induced by miR-143 and miR-145 (Figure 3d) .
A substitution mutation was generated to test the activities of the putative miRNA regulatory elements. As expected, we found that the mutation in the miRNA regulatory elements abolished the miR-143-or miR-145-mediated inhibition of the reporter gene (Figures 3e and f) . Taken together, these data suggest that the binding sites (1045 --1065 bp for miR-143 and 5114 --5136 bp for miR-145) that are present in the MDM2 3 0 UTR are critical for miR-143-and miR-145-mediated gene regulation.
P53 regulates the expression of miR-143 and miR-145
To determine whether miR-143 and miR-145 accumulation is transcriptionally or posttranscriptionally mediated by p53, and miR-145 inhibitors on the luciferase activity of pGL3-P1 or pGL3-P4. (e) Downregulation of the reporter gene with the wild-type region from MDM2 (MDM2-1045-WT) was apparent, whereas no effect on the MDM2-1045-MUT was detected. (f ) Downregulation of the reporter gene with the wild-type region (MDM2-5114-WT) was apparent, whereas no effect on the MDM2-5114-MUT was detected. These experiments were performed in triplicate, and the results are shown as the mean±s.d.
we used real-time PCR to measure the expression of miR-143 and miR-145 in the p53 wild-type HN30 cell line after treatment with Nutlin3, which is a small molecular inhibitor highly selective for inhibiting the MDM2-p53 interaction. 13 When endogenous p53 is upregulated, the expression of precursor and mature transcripts of miR-143 and miR-145 increased, although their primary transcript levels had no significant changes (Figures 4a and b) . Furthermore, knockdown of p53 by siRNA markedly reduced the levels of premiRNAs and mature miRNAs in HN30 cells (Figure 4c and d), indicating that these miRNAs are posttranscriptionally upregulated in a p53-dependent manner. Similar results were obtained in the SCC-25 cell line transfected with the wild-type p53 expressive vector, but not in the SCC-25 cell line treated with the mutated p53 expression vector (Figures 4e and f) . These data also suggest that the wild-type p53, not the mutated p53, upregulates miR-143 and miR-145, which is in consistency with the previous observation. 14 Kinetics of miR-143/145-MDM2-p53 expression following DNA damage To determine the kinetics of MDM2, p53 and miR-143/145 expression, we treated the HN30 and SCC-25 cells with 0.2 mg/ml adriamycin for different lengths of time. As expected, DNA damage resulted in oscillations of MDM2 and p53 expression in the HN30 cells (p53 wild-type; Figure 5a ), but not in the SCC-25 cells (p53-mutated type; Supplementary Figure S4 ). In addition, we used real-time PCR analysis to study the kinetics of miR-143/145 activation during p53 upregulation in the HN30 and SCC-25 cells. The kinetics of the expression of miR-143/145 directly correlated with the p53 protein upregulation (Figures 5b and c) .
Furthermore, we found that inhibiting p53 by siRNA treatment (Figure 5d ) attenuated the miR-143 and miR-145 pulse that occurred in response to continuous DNA damage in the HN30 cells (Figures 5e and f) . Additionally, blocking the miR-143/145 resulted in increased MDM2 levels, and the two-p53 pulses were substantially reduced in the HN30 cells (Figures 5g --i) .
To further identify miRs-MDM2-p53 oscillation induced by DNA damage stress, cancer cells were exposed to another common DNA damage stress, X-ray (2 Gy). The similar results like that treated with adriamycin were observed in HN30 cells (Supplementary Figure S5 ).
MiR-143 and miR-145 affect human squamous cell carcinoma cell growth To test whether reintroduction of these miRNAs affected the biology of the HNSCC cells, we observed higher p53 accumulation and MDM2 downregulation in the miRNA-transfected HN30 cells. These inversely opposing changes in the MDM2 and p53 expression levels correlated with higher activation of the p53 downstream targets of p21 and BAX (Figure 6a ). Given the known role of p21 and BAX in cell cycle regulation and apoptosis processes, 15, 16 we sought to determine whether miR-143/145 interfere with p21 and BAX function, block proliferation and induce apoptosis in HNSCC cells.
We examined the effect of miR-143 and miR-145 on cell proliferation using 5-ethynyl-2 0 -deoxyuridine (EdU) pulse labeling. The HN30 cells transfected with miR-143 and miR-145 exhibited 80% less EdU incorporation than did the miR-NC-transfected cells, but there was no difference in EdU incorporation in the SCC-25 cells (Figure 6b and Supplementary Figure S6) . Using flow cytometry analysis, we found that miR-143 and miR-145 blocked cell-cycle progression at the G1/S checkpoint in the HN30, NCI-H226 and TE-12 cells (Figure 6d ).
We examined whether cisplatin, an effective and commonly used therapeutic agent for patients with HNSCCs, synergistically increased cell apoptosis following expression of the miRNAs. As shown in Figure 6c and Supplementary Figure S7 Similar results like NH30 cells were observed in NCI-H226 cells derived from a human lung cancer and TE-12 cells derived from a human esophageal cancer (Figures 6a --d) . Importantly, both the NCI-H226 and TE-12 cell lines are squamous cell carcinomas derived from epithelial tissues and carry the wild-type p53 gene.
MDM2 mediates the growth resistance led by miR-143 and miR-145 in vitro and in vivo To determine whether MDM2 is the critical mediator of miR-143 and miR-145's role in cellular proliferation and cisplatin-induced apoptosis, we silenced MDM2 using RNA interference in human squamous cell carcinomas cell lines. Repression of MDM2 recapitulated the antiproliferative and pro-apoptotic effect of miR-143 and miR-145 on HN30 cells. Coexpression of a MDM2 cDNA lacking the 3 0 -UTR was able to abolish the miR-143 and miR-145-induced inhibition of cell proliferation and promotion of apoptosis (Figures 7a --c) , indicating that MDM2 as a mediator is involved in miR-143 and miR-145.
To determine whether miR-143 and miR-145 affect cell growth in a p53-depent manner, we co-transfected miR-143/145 and p53 siRNA into human squamous cell carcinomas cell lines. Repression (Figures 7a --c) . Similar results were also observed in TE-12 cells (Figures 7d --f) and NCI-H226 cells (Supplementary Figures S8a --c) . However, repression of p53 cannot attenuate miR-143 and miR-145-induced inhibition of cell proliferation and promotion of apoptosis in the SCC-25 cells (Supplementary Figures S8d --f) . These results indicate that miR-143 and miR-145 affect cell growth in a p53-depent manner in human squamous cell carcinomas.
We investigated the effect of these miRNAs on tumorigenicity in vivo. The tumors treated with miR-143, miR-145 and miR-pool (miR-143 combined with miR-145) showed decreased levels of the MDM2 protein and increased levels of the p53, p21 and BAX proteins (Figure 8a) . Also, miR-143, miR-145 and miR-pool increased the apoptotic rate and reduced the tumor weight of the mice compared with the miR-NC-treated group (Figures 8a --c) . These data indicate that miR-143 and miR-145 have therapeutic potential because of their ability to affect cell proliferation and apoptosis in HNSCC cells.
DISCUSSION
MDM2 is an oncogene that is frequently overexpressed in many human tumors and that enhances cellular transformation. 17 Studies have shown that the amplification of the MDM2 gene occurs more frequently in cancer patients with high-grade tumors. 18 Although MDM2 amplification has been found in many cases, the molecular mechanism that causes elevated MDM2 expression in most tumors remains unclear. Aside from activating gene mutations, several mechanisms could account for the upregulation of MDM2 function observed in cancer cells, including promoter demethylation, 19 transcriptional activation 20 and proteolytic degradation. 21 There is an increasing body of evidence suggesting that MDM2 may be regulated by other pathways, such as those associated with microRNA. 22 Recently, aberrant miRNA expression profiles in HNSCCs have been reported by several groups. 23, 24 However, the pathological roles and molecular mechanisms of the aberrantly expressed miRNAs in HNSCCs are poorly understood. The miR-143/145 cluster is particularly interesting, because these miRNAs possess tumor suppressor activity, and their expression is substantially reduced in several cancer types, including HNSCCs. 25 --31 In keeping with previous reports, our results revealed that miR-143 and miR-145 are underexpressed in most HNSCC samples. Many studies have identified several miR-143 and miR-145 targets, including K-RAS, 32 Fli1, 33 C-MYC 34 and DFF45. 35 These studies have also demonstrated that both miRNAs suppress tumors, decrease tumor proliferation or promote apoptosis. As is the case with many other miRNAs, the biological information available for miR-143 and miR-145 is largely limited to expression analysis. One significant obstacle that has limited the interpretation of many miRNAprofiling studies is that it is relatively difficult to identify the specific targets of the various miRNAs.
In this study, we identified MDM2 as a novel target of miR-143 and miR-145 in tumors. Furthermore, the ectopic expression of miR-143 and miR-145 leads to inhibition of MDM2 and the upregulation of p53 protein levels in HN30 cells. Given the association of p53 with miRNA in previous studies, 14 we reasoned that p53 may have a role in regulating the function of these miRNAs. To test this hypothesis, we specifically manipulated p53 expression in the HNSCCs cells. As expected, we found that knockdown of p53 led to decreased miR-143 and miR-145 expression, whereas overexpression of p53 led to increased miR-143 and miR-145 expression. According to the previous studies, p53 interacts with the Drosha complex through the DEAD-box RNA helicase p68, and facilitates the processing of primary miRNAs to precursor miRNAs.
14 They also found that the transcriptionally inactive p53 mutants interfere with a functional assembly between Drosha complex and p68, leading to attenuation of miRNA processing activity.
Previous studies have revealed that p53 levels oscillate when cells are subjected to DNA damage. 9 Our results showed that miR-143/145-dependent MDM2 turnover contributes to the control of p53 dynamics in response to DNA damage. Interestingly, although the oscillation amplitude is reduced, MDM2 can still be induced in response to DNA damage stress in p53-depleted cells. Previous studies have showed that some other signaling pathways can trigger the interaction of specific transcription factors with MDM2 gene, leading to the activation of transcription in addition to p53 in response to DNA damage, such as Ras --Raf --Mek --Erk pathway, 20, 36 and TGFb --Smad2 --Smad3 pathway. 37 In addition, it is proposed that MDM2 undergoes autoubiquitination when cells are challenged with DNA damage agents, 8 which also triggers the MDM2 oscillation partly. These results suggest that the destruction of MDM2 is controlled in p53-dependent and p53-independent pathways. Therefore, despite their roles as p53 downstream targets, miR-143 and miR-145 influence MDM2, which, in turn, leads to p53 activation in a positive feedback loop.
Specifically, decreased MDM2 expression by miR-143 and miR-145 is associated with increased expression of p21 and BAX. The altered expression of p21 and the BAX protein may partially account for the role of miR-143 and miR-145 in inhibiting tumor cell growth and inducing apoptosis. We demonstrated that restoration of high miR-143 and miR-145 expression levels in HNSCCs (HN30), human esophagus cancer (TE-12) and human lung cancer (NCI-H226) cell lines leads to decreased MDM2 and increased p53 protein levels. We noted that in the p53 wild-type cell lines, miR-143 and miR-145 were able to reduce EdU incorporation and block cell cycle progression at the G1/S check point. In addition, miR-143 and miR-145 have similar cisplatininduced apoptosis sensitizing effects on these p53 wild-type cell lines. In the SCC-25 cells, which represented the mutated-type p53 status in our cancer cell panel, transfection with miR-143 and miR-145 did not affect proliferation, cell cycle and apoptosis. These results indicate that miR-143 and miR-145 enhance proliferation suppression, cell cycle arrest and apoptosis in a p53-dependent manner. Our studies of in vivo regulation of miR-143 and miR-145 were complemented by functional studies demonstrating the role of these miRNAs in HNSCCs. We proved, both in vivo and in vitro, that these miRNAs cause MDM2 downregulation and subsequent p53, p21 and BAX upregulation. Thus, these miRNAs may have therapeutic value.
The results of our study lead us to conclude that under pathological conditions, such as cancer, MDM2 overexpression and the concomitant downregulation of miR-143 and miR-145 may be a potential p53-dependent mechanism underlying tumorigenesis. The ability of miR-143 and miR-145 expression to abrogate tumorigenesis by HNSCCs cells is probably the result of repression of a large set of oncogenic targets. The ability of these miRNAs to robustly suppress downstream MDM2 signaling as evidenced by activation of the p53 pathways probably has a central role in suppressing HNSCCs tumorigenesis.
In summary, our results have shown that miR-143/145, MDM2 and p53 form a novel regulatory network that controls HNSCCs cell growth and apoptosis (Figure 8d ). Deciphering this mechanism is an important step toward unraveling the regulatory network that underlies tumorigenesis, thereby bringing us closer to realizing the potential of miRNA in cancer treatment.
MATERIALS AND METHODS
Materials and reagents
Tissue samples were obtained from the Ninth People's Hospital of the Shanghai Jiao Tong University School of Medicine. The HN30 human HNSCCs cell line was obtained from the National Institutes of Health (NIH); the HNSCCs (SCC-25), human esophagus cancer (TE-12) and human lung cancer (NCI-H226) were obtained from American type culture collection (ATCC, Manassas, VA, USA). The miRNA mimics and inhibitors were purchased from Ambion (Austin, TX, USA). The MDM2, p53, p21 and BAX antibodies were purchased from ProteinTech Group (Chicago, IL, USA).
Plasmid construction
To obtain the luciferase constructs, different PCR-derived fragments from the MDM2 mRNA 3 0 UTR was inserted into the pGL3 control vector (Promega, Madison, WI, USA) at the Xba1 site. A PCR-based site-directed mutagenesis was performed to generate the mutant luciferase reporters. The open-reading frame of MDM2 was amplified and cloned into pcDNA3.0 vector.
Cell transfection
Transfection of cells was performed with Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. Briefly, the cells were seeded in 6-well or 24-well plates at 30% confluence the day before transfection. MiR-143/145 mimics/inhibitors and miRNA control (100 nM each) were used for each transfection.
Real-time PCR assay
Briefly, the total RNA was extracted with TRIzol (Invitrogen) and subjected to reverse transcription. The miRcute miRNA qPCR detection kit (TIANGEN, Shanghai, China) was used according to the manufacturer's protocol for detecting mature miRNAs. The results were normalized to U6 small nuclear RNA. For measurement of the primary and precursor miRNA expression, real-time PCR was performed using the SYBR method based on Suzuki's paper. 14 
Western blot assay
Cell lysates (30 mg) were electrophoresed through 10% polyacrylamide gels and transferred to a nitrocellulose membrane. The membrane was incubated with MDM2 antibody, p53 antibody, p21 antibody and BAX antibody. Secondary antibodies were labeled with IR Dyes. Signals were observed using an Odyssey Infrared Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
Luciferase assay
In all, 293 T cells were seeded in 24-well plates and transfected with luciferase reporters. The transfection efficiency was corrected by a Renilla luciferase vector (pRL-CMV, Promega). A luciferase assay kit (Promega) was used to measure the reporter activity according to the manufacturer's instructions.
Cell proliferation assay
Cell proliferation was determined by the EdU assay. EdU was readily incorporated into cellular DNA during DNA replication. Next, the terminal alkyne group was detected through its reaction with fluorescent azides in a Cu (I)-catalyzed [3 þ 2] cycloaddition.
Cell cycle analysis
For the flow cytometry analysis, the cells were trypsinized and fixed in 70% ice-cold ethanol overnight. The cells were then incubated in a 0.5-ml propidium iodide solution (Sigma, St Louis, MO, USA; 50 mg/ml in PBS) plus 25 mg/ml RNase for 15 min at 37 1C and measured.
Cell apoptosis assay Cancer cells were transfected with 100 nM miR-143/145 mimics for 24 h, and then treated with 1 mg/ml cisplatin for 24 h. Cells were harvested and resuspended with 500 ml of binding buffer. The cell suspension (100 ml) was incubated with 5 ml annexin-V and propidium iodide at room temperature for 20 min. The stained cells were analyzed with fluorescent-activated cell sorting using BD LSR II flow cytometry (Becton Dickinson, San Jose, CA, USA).
The ScienCell Colorimetric TUNEL apoptosis assay was used to detect apoptosis in the HNSCCs cell xenograft tumor tissues. In brief, the 3 0 OH end of the DNA strand was labeled with biotinylated nucleotides. Streptavidin-conjugated HRP was subsequently bound to the biotinylated nucleotides and visualized using the peroxidase substrate 3, 3 0 -diaminobenzidine.
Mouse experiments
The HN30 cells (5 Â 10 6 ) were injected into the right flanks of athymic nu/nu mice. One week after the injections, mice with comparably sized tumors were treated for 4 weeks with miR-143, miR-145 and miR-pool (miR-143 combined with miR-145). The miRNA mimics (2 nmol) were injected directly into the tumors twice weekly for 4 weeks.
Statistical analysis
The categorical variables were compared among the groups using the w
